28 - State-of-the-Art HIV Care and Prevention

Thursday, October 17, 2024

10:30 AM – 11:45 AM US PT

Location: Concourse 151

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Vivek Jain, MD, MAS (he/him/his)

Professor of Medicine
Division of HIV, Infectious Diseases & Global Medicine, San Francisco General Hospital, University of California, San Francisco
San Francisco, CA, United States
Damani Piggott, MD, PhD

Associate Professor
Medicine
Johns Hopkins University School of Medicine
Baltimore, MD, United States

Faculty(s)

Raphael Landovitz, MD, MSc

Professor of Medicine; Director
UCLA Center for Clinical AIDS Research & Education
Los Angeles, CA, United States
Michael Reid, MD MPH (he/him/his)

Chief Science Officer
PEPFAR, Bureau of Global Health Security and Diplomacy, US State Department
San Francisco, CA, United States
SK

Susan Koletar, MD

Professor, Director
Internal Medicine/Infectious Diseases
Ohio State University
Columbus, Ohio, United States

Disclosure(s):

Vivek Jain, MD, MAS: Shionogi: Advisor/Consultant (Terminated, April 30, 2022)

Damani A. Piggott, MD, PhD: No financial relationships to disclose

Raphael J. Landovitz, MD, MSc: Gilead Sciences: Advisor/Consultant (Ongoing), Scientific Advisory Board member (Ongoing); Merck and Company, Inc.: Advisor/Consultant (Ongoing), Scientific Advisory Board member (Ongoing); RedQueen Therapeutics: Advisor/Consultant (Ongoing), Scientific Advisory Board member (Ongoing); Viiv Healthcare: Advisor/Consultant (Ongoing), Scientific Advisory Board member (Ongoing)

Michael J A Reid, MD MPH: No financial relationships to disclose

Susan L. Koletar, MD: No financial relationships to disclose

Learning Objectives:

At the conclusion of this session, participants will be able to:

analyze the role of long-acting injectable antiretroviral therapy for hiv treatment and prevention;
describe strategies for and progress towards providing universal access to antiretroviral therapy within the pepfar program;
describe advances in antiretroviral therapy for hiv treatment and prevention.

Presentations:

10:30 AM – 10:50 AM US PT

What's the latest data and experience on LAI treatment and prevention?
Speaker: Raphael J. Landovitz, MD, MSc – UCLA Center for Clinical AIDS Research & Education
10:50 AM – 11:10 AM US PT

PEPFAR: Strategies to accelerate towards ending the epidemic and sustaining the gains
Speaker: Michael J A Reid, MD MPH (he/him/his) – PEPFAR, Bureau of Global Health Security and Diplomacy, US State Department
11:10 AM – 11:30 AM US PT

Treatment and prevention pipeline: What's coming?
Speaker: Susan L. Koletar, MD – Ohio State University
11:30 AM – 11:45 AM US PT

Update on Lenacapavir for PrEP: Results from the Interim Analyses of PURPOSE 1 and PURPOSE 2
Speaker: Colleen F. Kelley, MD, MPH (she/her/hers) – Emory University